Skip to content

Ketamine: all studies

Page 425 of 449: studies 4,241 to 4,250 of 4,486, newest first. Back to the ketamine overview

Research

Neuropharmacological characterization of the new psychoactive substance methoxetamine

Neuropharmacology September 1, 2017 Laura Hondebrink, E. Kasteel, A. Tukker et al.

&NA; The use of new psychoactive substances (NPS) is steadily increasing. One commonly used NPS is methoxetamine (MXE), a ketamine analogue. Several adverse effects have been reported following MXE exposure, while only limited data are available on its neuropharmacological modes of action. We investigated the effects of MXE and ketamine on several endpoints using multiple in vitro models. These...

Backing into the future: pharmacological approaches to the management of resistant depression

Psychological Medicine August 25, 2017 Philip J. Cowen 38 citations

Pragmatic studies indicate that a substantial number of depressed patients do not remit with current first-line antidepressant treatments and after two failed treatment steps the chance of remission with subsequent therapies is around 15%. This paper focuses on current evidence for pharmacological treatments in resistant depression as well as possible future developments. For patients who have...

Novel Psychoactive Substances—Recent Progress on Neuropharmacological Mechanisms of Action for Selected Drugs

Frontiers in Psychiatry August 18, 2017 Zurina Hassan, Oliver G. Bosch, Darshan Singh et al. 62 citations

A feature of human culture is that we can learn to consume chemical compounds, derived from natural plants or synthetic fabrication, for their psychoactive effects. These drugs change the mental state and/or the behavioral performance of an individual and can be instrumentalized for various purposes. After the emergence of a novel psychoactive substance (NPS) and a period of experimental...

DOI: 10.3389/fpsyt.2017.00152 (opens in new tab) Psychotropic drugs Mind-altering substances Novel compounds Medical benefits +6

Exploring a post-traumatic stress disorder paradigm in Flinders sensitive line rats to model treatment-resistant depression II: response to antidepressant augmentation strategies.

Acta Neuropsychiatrica August 2017 Sarel Jacobus Brand, Brian Herbert Harvey

Post-traumatic stress disorder (PTSD) displays high co-morbidity with major depression and treatment-resistant depression (TRD). Earlier work demonstrated exaggerated depressive-like symptoms in a gene×environment model of TRD and an abrogated response to imipramine. We extended the investigation by studying the behavioural and monoaminergic response to multiple antidepressants, viz....

DOI: 10.1017/neu.2016.50 (opens in new tab) Full text (opens in new tab) Nmda antagonist Animal model Noradrenaline reuptake inhibitor Serotonin reuptake inhibitor +1

Two Fatal Intoxications Involving 3-Methoxyphencyclidine.

Journal of Analytical Toxicology July 1, 2017 Christie Mitchell-Mata, Brittany Thomas, Brianna L Peterson et al.

3- and 4-methoxyphencyclidine (3-MeO-PCP, 4-MeO-PCP), structural analogs of phencyclidine (PCP), were among the first legal PCP alternatives to show up on the novel psychoactive substances (NPS) market in Europe in the 2000s. Their structural similarities to PCP and ketamine likely contribute to their demonstrated dissociative anesthetic effects. Limited information exists in the literature...

Prevalence of new psychoactive substances and prescription drugs in the Belgian driving under the influence of drugs population

Drug Testing and Analysis June 22, 2017 Sarah M.r. Wille, Camille Richeval, M. Nachon‐phanithavong et al. 68 citations

Driving under the influence of drugs (DUID) is a worldwide problem. Several countries have adopted DUID legislations which prove their deterrent effect and impact on road safety. However, the use of new psychoactive substances (NPS) and prescription drugs is not known, as the applied roadside screening tests have not yet been adapted for these compounds. In this study, 558 blood samples...

DOI: 10.1002/dta.2232 (opens in new tab) Pharmacology Psychoactive drug Population Mephedrone +5

Atypical binding at dopamine and serotonin transporters contribute to the discriminative stimulus effects of mephedrone.

Neuropharmacology June 2017 Alyssa F DeLarge, Laura L Erwin, Peter J Winsauer

Mephedrone (4-methylmethcathinone), a constituent of the recreational substances known as "bath salts", is a synthetic cathinone that can produce auditory and visual hallucinations, as well as problematic cardiovascular effects. This study compared the discriminative stimulus effects of mephedrone (0.32-10 mg/kg) with other prototypical drugs of abuse: cocaine (0.56-32 mg/kg), d-amphetamine...

DOI: 10.1016/j.neuropharm.2017.04.006 (opens in new tab) Full text (opens in new tab) Bath salts Cathinone Desipramine Drug discrimination +3

Salvinorina A: terpeno alucinógeno presente en Salvia divinorum Epling & Játiva

Colombia Forense April 10, 2017 Valentina Soto-Restrepo, Gonzalo Taborda Ocampo, William F. Garzón Mendez

Tema y alcance: el objetivo de esta revisión es presentar los estudios químicos que se han realizado sobre Salvia divinorum E&J en estos últimos años. Características: desde la década de 1990 hasta hoy se ha incrementado la distribución y el uso de Salvia divinorum E&J para “fines recreativos”, debido a sus efectos alucinógenos y a su fácil acceso. Sus efectos en el organismo se han relacionado...

The Subjective Response to Nitrous Oxide is a Potential Pharmaco-Endophenotype for Alcohol Use Disorder: A Preliminary Study with Heavy Drinkers.

The International Journal of Neuropsychopharmacology April 1, 2017 Katie Walsh, Ravi Das, Sunjeev K. Kamboj

Healthy people with a family history of alcohol problems show a pattern of subjective responses to alcohol that resemble those of affected probands. Studies on ketamine suggest that up-regulation of N-methyl-D-aspartate receptors (NMDARs) underlies these effects, and point to a pharmacologically-responsive endophenotype reflecting enhanced risk for alcohol-use disorders. Subjective stimulant...

What are sweet dreams made of? Analysis of psychoactive substances into “gummies”: A retrospective descriptive study

European Psychiatry April 1, 2017 Amira Trabsa, E. Monteagudo, D.d. Mariona et al. 2 citations

Introduction Although psychoactive substances has a long history in recreational settings, research on its composition has focused only on tablets, crystal and powder, even though new formulation for new psychoactive substances are readily available for users. Objectives To describe the presence of psychoactive substances and its characteristics in new formulations which had not previously been...